Tosh, JL;
Rhymes, ER;
Mumford, P;
Whittaker, HT;
Pulford, LJ;
Noy, SJ;
Cleverley, K;
... Wiseman, FK; + view all
(2021)
Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models.
Scientific Reports
, 11
(1)
, Article 5736. 10.1038/s41598-021-85062-3.
Preview |
Text
Wiseman_Genetic dissection of down syndrome-associated alterations in APP:amyloid-β biology using mouse models_VoR.pdf - Published Version Download (3MB) | Preview |
Abstract
Individuals who have Down syndrome (caused by trisomy of chromosome 21), have a greatly elevated risk of early-onset Alzheimer's disease, in which amyloid-β accumulates in the brain. Amyloid-β is a product of the chromosome 21 gene APP (amyloid precursor protein) and the extra copy or 'dose' of APP is thought to be the cause of this early-onset Alzheimer's disease. However, other chromosome 21 genes likely modulate disease when in three-copies in people with Down syndrome. Here we show that an extra copy of chromosome 21 genes, other than APP, influences APP/Aβ biology. We crossed Down syndrome mouse models with partial trisomies, to an APP transgenic model and found that extra copies of subgroups of chromosome 21 gene(s) modulate amyloid-β aggregation and APP transgene-associated mortality, independently of changing amyloid precursor protein abundance. Thus, genes on chromosome 21, other than APP, likely modulate Alzheimer's disease in people who have Down syndrome.
Archive Staff Only
 |
View Item |
